We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.44B
AUM Growth
-$102M
Cap. Flow
-$54M
Cap. Flow %
-2.21%
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$45.2M
2
HUM icon
Humana
HUM
+$23.9M
3
LLY icon
Eli Lilly
LLY
+$20.3M
4
ILMN icon
Illumina
ILMN
+$20.1M
5
ABT icon
Abbott
ABT
+$17.5M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$44.1M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$23.1M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$21.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Real Estate 1.86%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
126
GSK
GSK
$103B
$1.23M 0.05%
+41,852
New +$1.59M
AFMD
127
DELISTED
Affimed
AFMD
$1.21M 0.05%
58,604
– –
STVN icon
128
Stevanato
STVN
$5.36B
$1.21M 0.05%
71,190
– –
ACAD icon
129
Acadia Pharmaceuticals
ACAD
$4.65B
$1.18M 0.05%
72,225
– –
NVAX icon
130
Novavax
NVAX
$1.26B
$1.16M 0.05%
63,800
– –
RNAM
131
DELISTED
Avidity Biosciences
RNAM
$1.05M 0.04%
64,618
-20,600
-24% -$394K
NTRA icon
132
Natera
NTRA
$39.4B
$938K 0.04%
21,400
– –
ASRT
133
DELISTED
Assertio
ASRT
$932K 0.04%
27,372
– –
STRO icon
134
Sutro Biopharma
STRO
$425M
$910K 0.04%
16,392
– –
BEAM icon
135
Beam Therapeutics
BEAM
$2.92B
$754K 0.03%
15,817
– –
SRRK icon
136
Scholar Rock
SRRK
$5.73B
$754K 0.03%
108,833
– –
ICPT
137
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$726K 0.03%
52,067
– –
NBP
138
NovaBridge Biosciences American Depositary Shares
NBP
$191M
$652K 0.03%
162,580
– –
ARDX icon
139
Ardelyx
ARDX
$1.24B
$642K 0.03%
539,408
– –
ALXO icon
140
ALX Oncology
ALXO
$265M
$634K 0.03%
66,211
– –
TCRX icon
141
TScan Therapeutics
TCRX
$48.1M
$610K 0.03%
200,000
– –
FUSN
142
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$605K 0.02%
101,931
+58,537
+135% +$146K
THRX
143
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$580K 0.02%
100,000
– –
ACET icon
144
Adicet Bio
ACET
$86.1M
$573K 0.02%
2,521
-1,437
-36% -$365K
NHI icon
145
National Health Investors
NHI
$3.61B
$567K 0.02%
10,038
– –
ONEM
146
DELISTED
1Life Healthcare
ONEM
$536K 0.02%
31,266
– –
CHCT
147
Community Healthcare Trust
CHCT
$506M
$488K 0.02%
14,900
– –
UHT
148
Universal Health Realty Income Trust
UHT
$587M
$486K 0.02%
11,258
– –
CDXS icon
149
Codexis
CDXS
$154M
$419K 0.02%
+69,125
New +$556K
MOR
150
DELISTED
MorphoSys AG American Depositary Shares
MOR
$412K 0.02%
81,867
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Tekla Capital Management held 187 positions worth $2.44B, down 4% from $2.54B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q3 2022 filing shows 10 new, 35 increased, 38 reduced and 19 closed positions. Its largest new stake was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M. The largest sale was McKesson, an estimated $44.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2022 buy was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M.
  • Tekla Capital Management added most to Johnson & Johnson in Q3 2022, an estimated $45.2M increase.
  • Tekla Capital Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $44.1M.
  • Tekla Capital Management fully exited Syneos Health, Inc. Class A Common Stock in Q3 2022, selling an estimated $21.7M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.44B portfolio in Q3 2022.
  • Tekla Capital Management opened 10 new positions and closed 19 in Q3 2022.
  • Tekla Capital Management's portfolio value fell 4% quarter-over-quarter to $2.44B.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.